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Myocardial amiodarone and desethylamiodarone concen-
trations were measured at multiple sites in the explanted
heart in four patients who underwent cardiac transplanta-
tion. Patients were taking amiodarone, 200 to 400 mg/day
(mean 300 ± 115), for 88 to 428 days (mean 229 ± 148). The
mean cumulative dose was 58 ± 21.3 g. Plasma amiodarone
concentration in three subjects was 204, 312 and 419 ng/ml
and desethylamiodarone concentration was 268, 513 and
880 ng/ml, respectively.
Significant interindividual variability in myocardial con-
centrations of amiodarone and desethylamiodarone was
observed (p < 0.05). Mean myocardial amiodarone concen-
tration ranged from 4 ± 1.0 to 29 ± 17.2 J,Lg/g (p < 0.05);
mean desethylamiodarone concentration ranged from 22 ±
The complex distribution and elimination of amiodarone has
been noted in clinical studies evaluating its plasma pharma-
cokinetics (l,2). For many cardioactive agents drug concen-
tration is significantly higher in myocardium, the site of
action, compared with plasma. That this is also the case for
amiodarone has been reported in animals (3,4), as well as in
single biopsy specimens in humans (5,6). Desethylamio-
darone, its major metabolite, is also found in very high
concentrations in lung, liver, fat and myocardium (6). Both
drugs have important cardiac electrophysiologic effects and
desethylamiodarone has even more potent effects on prolon-
gation of the QRS duration, atrial refractory period and
ventricular refractory period than the parent compound
(7,8). Accumulation of desethylamiodarone has been sug-
gested as a source for the delayed electrophysiologic effect
in patients receiving long-term treatment with amiodarone.
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8.8 to 141 ± 102. 5 J,Lg/g (p < 0.05). At each site, save for
fat, myocardial desethylamiodarone concentration was
higher than amiodarone concentration. Greater intraindi-
vidual variability was observed in myocardial desethylami-
odarone compared with amiodarone concentration partic-
ularly in septal and scar tissue (p =NS).
No significant relation was found between myocardial
concentration and duration of treatment. In patients with
significant ventricular disease, usefulness of plasma amio-
darone and desethylamiodarone concentration to estimate
myocardial concentration is limited by intra- and interin-
dividual variability.
(J Am Coil CardioI1990;16:943-7)
Evaluation of myocardial concentration of parent drug
and metabolite could improve our understanding of their
electrophysiologic effects and mechanism of action of drug.
However, it is unclear whether there is significant variability
of parent and metabolite concentrations in the heart. The
purpose of this study was 1) to describe amiodarone and
desethylamiodarone concentrations at selected sites in the
explanted heart, and 2) to examine for intra- and interindi-
vidual variability in myocardial concentrations in four pa-
tients who underwent cardiac transplantation.
Methods
Myocardial samples. Samples of cardiac muscle from the
right and left atria and ventricles were taken at the time of
cardiac transplantation from the explanted heart of four
patients to measure drug concentration. A stitch was placed
on the cephalad aspect of each specimen to identify the site;
samples were blotted dry and immediately frozen. Each
explanted heart had areas of fibrosis and scar and, in
addition, one (Patient 3) had a thinned area in the apex of the
left ventricle and another (Patient 4) had a discrete aneu-
rysm. Myocardial samples were selected so that drug con-
centration could be measured in areas representing central
(site A) and peripheral (site B) regions of scar.
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Daily
Amiodarone Dose Duration of RV + LV
Patient (mg: mg/kg body Treatment Weight
No. Age (yn/Gender weight! (days) Heart Disease' (g)
48/M 200: 2.9 428 CAD. cardiomyopathy. 278
EF 12~
2 50/M 400: 3.6 88 CAD. cardiomyopathy. 332
EF 20~
3 45/M 200: 2.9 247 Cardiomyopathy. 650
EF 15~. AICD
4 47/M 400: 4.7 152 CAD. cardiomyopathy. 345
EF 15%
Mean 48 300: 3.5 229 401
±SD 2 115: I 148 168
'Diagnosis from pathology report. AICD = automatic implantable cardioverter-defibrillator: CAD = coronary
artery disease: EF = ejection fraction: LV = left ventricle: M = male: RV = right ventricle.
At the time of analysis myocardial samples were de-
frosted, blotted. dried and cut. The samples measured ap-
proximately 3 x 3 mm and weighed 0.085 ± 0.044 g (range
0.204 to 0.033). After weighing, samples were placed into
Ten Broeck tissue grinders with 2 ml of methanol (ACS
grade), hand homogenized and transferred to test tubes. The
resulting solution was then evaporated to dryness. After
evaporation was complete, 0.5 ml of internal standard
(3 ILg!mI), I ml acetate buffer (1 M) and 5 ml hexane were
added to each test tube. The solution was mixed at low speed
for 5 min and then centrifuged for 10 min. The resulting
organic layer was transferred to a test tube and evaporated
to dryness, reconstituted with 150 ILl of mobile phase and
50 ILl aliquots were injected into the injection portal.
Plasma samples to measure amiodarone and desethylami-
odarone concentrations. These were taken 14 h after the last
drug dose on the day of transplant surgery. Plasma samples
were measured for amiodarone and desethylamiodarone by
combining I ml plasma, I ml acetate buffer (I M). 20 ILl
internal standard (80 ng!ILl) and 5 ml hexane in a test tube.
The solution was mixed at a low speed for 5 min and then
centrifuged for 10 min. The resulting organic layer was
transferred to a test tube and evaporated to dryness. The
contents of the tube were reconstituted with 150 ILl of mobile
phase and 50 ILl samples were injected into the injection
portal. The concentration of the plasma samples was deter-
mined from a standard curve.
Apparatus. Analyses were performed using a model 440
high performance liquid chromatograph (Waters Associates)
interfaced with a 740 Data Module. An M45 solvent delivery
system and a U6k injector were employed. Chromatography
was performed using a Millipore Z Module radial compres-
sion separation system with a CN IO ILm (5 mm x 10 cm)
Radial Pak cartridge (Waters Associates). The flow rate was
1.0 ml/min operating at a pressure < 1,500 psi. The detector
wavelength was set at 254 nm.
Mobile phase. The mobile phase consisted of 0.05 M
perchloric acid (HCI04) and Acetonitrile (HPLC grade)
(50:50) plus I M heptane sulfonate (5 ml/liter of mobile
phase). The solution was made daily, filtered and degassed.
The flow rate was I mllmin with a pressure < I,500 psi.
Statistical analysis. Repeated measures of analysis of
variance were used to test the null hypothesis that there is no
difference between amiodarone and desethylamiodarone
concentrations at sites throughout the heart and among
patients. Data were normalized for dose size and are ex-
pressed as range and mean value ± SD. A p value <0.05 was
considered significant.
Results
Patient characteristics (Table 1). All four patients had
reduced ejection fraction (range 12% to 20%, mean 16 ±
3.3%) and were diagnosed as having cardiomyopathy: three
had coronary artery disease and one had normal coronary
arteries. All patients were men and ranged in age from 45 to
50 years (mean 48 ± 2) and were taking amiodarone, 200 to
400 mg/day (mean 300 ± 115) for 88 to 428 days (mean 229 ±
148). The mean cumulative daily dose (daily dose x duration
of treatment) was 58 ± 21.3 g: 85.6, 35.2, 49.2 and 60.8 g,
respectively, in patients I to 4. Patients 2, 3 and 4 were also
taking digoxin.
All four patients had a malignant ventricular arrhythmia
as the indication for starting amiodarone therapy: ventricular
tachycardia at a rate of 140 to 160, 200 to 210 and 140 to 150
beats/min, respectively, in Patients I, 2 and 4, and cardiac
arrest with recurrent ventricular tachycardia requiring an
automatic implantable defibrillator in Patient 3.
Plasma drug concentrations (Table 2) measured before
explantation for Patients I. 2 and 3, respectively, were 419,
204 and 312 ng/ml for amiodarone and 513, 268 and 880 ng/ml





Table 2. Amiodarone and Desethylamiodarone Myocardial Concentration in Four Patients
Patient No.
(ratio)* 2 (ratio)* (ratio)* 4
Tissue amiodarone (j.tg/g)
Atrium
Right 9 (21) 3 (15) 11 (35)
Left 11 (26) 4 (20) 12 (38)
Ventricle
Right 5 ([2) 3 (15) 14 (45)
Left 6 (14) 4 (20) 16 (51) 45
Septum
High 5 ([2) 4 (20) 13 (42) 49
Low 3 (7) 4 (20) 8 (26) 23
Scar
Central (A) 6 (14) 6 (29) 6 (19) 8
Peripheral (8) 7 (17) 3 (15) 6 (19) 22
Mean ± SO 7 ± 2.5 (15 ± 6) 4 ± 1.0 (19 ± 5) 11 ± 3.7 (34 ± 12) 29 ± 17.2
Fat
Right ventricle 275 (656) 32 (157) 125 (401)
Left ventricle 151 (360) 17 (83) 218 (699)
Plasma amiodarone (ng/mll 419 204 312





Right 40 (78) 15 (56) 31 (35)
Left 30 (58) 19 (71) 39 (44)
Ventricle
Right 22 (42) 19 (71) 63 (72)
Left 31 (60) 14 (52) 69 (78) 214
Septum
High 26 (50) 25 (93) 55 (63) 279
Low 18 (35) 34 (127) 30 (34) 104
Scar
Central (A) 12 (23) 37 (138) 24 (27) 29
Peripheral (B) 28 (55) 16 (60) 22 (25) 80
Mean ± SO 26 ± 8.6 (50 ± 17) 22 ± 8.8 (84 ± 33) 42 ± 18.3 (47 ± 21) 141 ± 102.5
Fat
Right ventricle 90 (174) 21 (78) 39 (44)
Left ventricle 42 (81) 15 (56) 74 (84)
Plasma desethylamiodarone 513 268 880
(ng/mll
*Numbers in parentheses are ratio of tissue concentration to plasma concentration.
for desethylamiodarone. In Patient 4 plasma samples and
myocardial samples from atria, left ventricle and fat were not
assessed because of a power failure during freezer storage
that resulted in spoiled samples.
Amiodarone myocardial concentration (Table 2). At
pathologic examination explanted myocardium consisting of
right and left ventricle weighed 278 to 650 g (mean 401 ±
168). At transplantation the atria were not entirely surgically
removed, thus accounting for the relatively normal heart
weight for Patients 1. 2 and 4. Significant interindividual
variability in myocardial amiodarone concentration was ob-
served (p < 0.05) even when normalized for dose size (p <
0.05). There was no significant relation between concentra-
tion and cumulative dose. The following ranges of myocar-
dial amiodarone concentration (JLg/g) were noted: right
atrium, 3 to II (mean 8 ± 4); left atrium, 4 to 12 (mean 9 ±
4); right ventricle, 3 to 14 (mean 7 ± 6); left ventricle, 4 to 45
(mean 18 ± 19); high septum, 4 to 49 (mean 18 ± 21); low
septum, 3 to 23 (mean 10 ± 9); scar site A, 6 to 8 (mean 7 ±
I); scar site B, 3 to 22 (mean 10 ± 9); fat adherent to right
ventricle, 32 to 275 (mean 144 ± 123); fat adherent to left
ventricle, 17 to 218 (mean 129 ± 102). Myocardial amio-
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darone concentration was greater than plasma concentration
and this ratio ranged from 7 to 51 (mean 23 ± II). Amio-
darone concentration was highest in fat and, consequently,
the fat to plasma amiodarone ratio was higher, 83 to 699
(mean 393 ± 251).
Plasma amiodarone concentration did not reflect myo-
cardial amiodarone concentration, as illustrated by two
patients taking the same dose, 2.9 mg/kg body weight per
day. Patient I, who had an amiodarone plasma concentration
of 419 ng/ml, had a low myocardial amiodarone concentra-
tion ranging from 3 to II IJ-g/g (ratio 7 to 26). In contrast, the
plasma amiodarone concentration of Patient 3 was lower
(312 ng/mO, but the myocardial amiodarone concentration
was higher (range 6 to 16IJ-g/g) (ratio 19 to 51) (Table 2). In
these two patients plasma desethylamiodarone concentra-
tions, 513 and 880 ng/ml, respectively, were associated with
high myocardial metabolite concentrations: I) range 12 to 40
1J-gig (ratio 23 to 78) for Patient I, and 2) range 22 to 69 ~/g
(ratio 25 to 78) for Patient 3.
Desethylamiodarone myocardial concentration (Table 2).
As with amiodarone, there was interindividual variability in
myocardial desethylamiodarone concentration (p < 0.05)
and no relation between concentration and cumulative dose.
Myocardial desethylamiodarone concentration was higher
than amiodarone concentration at each site except for fatty
tissue. Intraindividual variability was greater for desethyl-
amiodarone than for amiodarone, as noted by the wider
standard deviation; however, this difference was not statis-
tically significant. The following ranges of myocardial des-
ethylamiodarone concentrations (IJ-g/g) were noted: right
atrium, 15 to 40 (mean 29 ± 14): left atrium, 19 to 39 (mean
29 ± 10); right ventricle, 19 to 63 (mean 35 ± 26); left
ventricle, 14 to 214 (mean 82 ± 91); high septum, 25 to 279
(mean 96 ± 123); low septum, 18 to 104 (mean 47 ± 39); scar
site A, 12 to 37 (mean 26 ± 10); scar site B, 16 to 80 (mean
37 ± 29); fat adherent to right ventricle. 21 to 90 (mean 50 ±
36); fat adherent to left ventricle, 15 to 74 (mean 44 ± 30).
Myocardial desethylamiodarone concentration was greater
than plasma concentration (range 12 to 69 1J-gig; ratio range
23 to 138).
Scar. In accord with findings in other sites, desethylami-
odarone concentration in scar was higher (mean 31 ± 21
IJ-g/g) than that of amiodarone (mean 8 ± 6 IJ-g/g). Patient 4,
who had a discrete left ventricular aneurysm, had a twofold
difference in amiodarone concentration between central and
peripheral sites and high and low septal tissue. In addition,
there was variability of desethylamiodarone concentration in
central and peripheral scar tissue in Patients I, 2and 4and in
high and low septal tissue of all patients.
Discussion
The opportunity to characterize myocardial drug concen-
tration of amiodarone and its cardioactive metabolite, des-
ethylamiodarone, was provided by analysis of myocardial
samples from four patients who underwent cardiac trans-
plantation. Two previous reports (6,9) presented myocardial
amiodarone concentrations in biopsy specimens from the
right atrium; this report describes myocardial determinations
of amiodarone and desethylamiodarone concentrations from
four cardiac chambers. Interindividual variability in plasma
and myocardial concentrations in patients taking similar or
equivalent (mg/kg) doses was observed (p < 0.05). Concor-
dant amiodarone concentration was observed within right
and left cardiac chambers. Intraindividual variability was
more marked for desethylamiodarone than for amiodarone at
all myocardial sites.
Electrophysiologic effects. Both amiodarone and its me-
tabolite have important cardiac electrophysiologic effects
and desethylamiodarone has even more potent effects on
prolongation of the QRS duration, atrial refractory period
and ventricular refractory period than does the parent com-
pound (7,8). Abnormalities of conduction and refractoriness
in depressed tissue underlie the mechanism of many arrhyth-
mias, and disparate drug concentration within or near the
arrhythmic site could cause further inhomogeneity of con-
duction or refractoriness accounting for inadequate efficacy
or worsening of some arrhythmias. Clinical observations
(10). although largely unproved, suggest that arrhythmia
suppression is more difficult to achieve and proarrhythmia
more likely in patients with significant left ventricular dis-
ease and scarring. The observations here, whereby anatomic
abnormalities are associated with variable drug concentra-
tions among patients, support the view that the antiarrhyth-
mic effect of amiodarone is more reliably guided by clinical
outcome or electrophysiologic testing than by plasma drug
concentration (II).
Cationic amphiphilic drugs. Several possibilities to ac-
count for the variable drug concentrations among the four
patients were considered, including perfusion in and out of
myocardial areas sampled, degree of fibrosis, number and
extent of drug receptors and binding, and myocardial lipid
accumulation. Amiodarone and desethylamiodarone are
classified as cationic amphiphilic drugs and. like others of
this class, are potent inhibitors of lysosomal phospholipase
activity, a primary mechanism whereby phospholipidosis is
induced (12). Ultrastructural changes indicate that amio-
darone therapy is associated with lamellar inclusion bodies
found in lung, liver. lymph nodes and cornea (13). Recently,
similar lysosomal inclusion bodies have been identified in the
canine myocardium (14) characterized by variable and
patchy distribution. Because amiodarone and desethylamio-
darone appear to increase in parallel with phospholipid (15),
these ultrastructural changes may account for variability in
lipid concentration and consequent amiodarone and deseth-
ylamiodarone content as well.
Conclusions. Measurement of plasma concentration of-
ten is useful for assessing drug effect. particularly when





inadequate or excessive drug concentration is suspected.
However, as observed here, drug concentration measured in
the plasma may not predict myocardial concentration. A
limitation of our study is the small study group consisting of
four subjects with severely depressed left ventricular func-
tion. It is not clear if the drug variability among these
patients observed after oral amiodarone therapy holds for
patients with normal or minimally depressed ventricular
function or for other antiarrhythmic drugs whose pharmaco-
kinetics differs and is less complex than that of amiodarone.
Intra- and interindividual variability in myocardial concen-
tration limits the usefulness of amiodarone and desethylami-
odarone plasma drug concentration for predicting drug effect
and may account for lack of efficacy or untoward events
despite apparent therapeutic plasma concentration.
We are grateful to Robert Sciacca, Eng, SeD for analysis of the statistical
data.
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